New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI

In 2019, Nubeqa (darolutamide) became the fourth 2nd generation anti-androgen to be FDA approved. There were hints that this medication could have less instances of fatigue when compared to other 2nd generation anti-androgens like Zytiga. However, at the time it was only approved for men in the very specific situation of having prostate cancer that was resistant to standard hormone therapy but non-metastatic. On August 5, 2022, the FDA extended its approval for darolutamide for men with hormone-sensitive metastatic disease. This news coincides well with other studies that are beginning to show greater efficacy with these medications when used as early as possible in the advanced disease course, for example, when metastases are present and before developing hormone resistance, and while it may have been possible for men in this situation to access Zytiga, darolutamide should now be an accessible option for men who are experiencing severe side effects and want to try a different medication.

0:09 What is 'hormone-sensitive' prostate cancer?

1:11 What is darolutamide?

2:24 Can you clarify the difference between standard or first-generation hormone therapy and 2nd generation hormone therapies?

3:06 What are the side effects of darolutamide?

4:19 Do the same strategies to mitigate side effects of standard hormone therapy apply to darolutamide and other 2nd generation hormone therapies?

7:26 If someone is on Zytiga or Erleada and they want to try darolutamide, should they talk to their doctor about it?

7:54 Is PSA decline a good metric for knowing of darolutamide is working?

8:48 How long should a patient wait to see if there is an acceptable PSA decline before moving on to different therapies?

9:05 Can you do intermittent hormone therapy with a drug like darolutamide?

10:09 How long does it take testosterone to recover after darolutamide?

Don’t know your stage? Take the quiz: Visit

To learn more about prostate cancer visit

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI:

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #MarkScholzMD #PCRI
Be the first to comment